Complete remission of psoriasis following bevacizumab therapy for colon cancer

A Akman, E Yilmaz, H Mutlu… - Clinical and experimental …, 2009 - academic.oup.com
A Akman, E Yilmaz, H Mutlu, M Ozdogan
Clinical and experimental dermatology, 2009academic.oup.com
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF),
which is used to treat several cancers. Currently, experience with anti‐VEGF treatment for
psoriasis is limited, and no published reports on this use exist. We describe a patient with
metastatic colon cancer and psoriasis who experienced complete remission of psoriasis
during treatment with bevacizumab and combination chemotherapy without any other
treatment for psoriasis. These data suggest that bevacizumab may be a promising …
Summary
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which is used to treat several cancers. Currently, experience with anti‐VEGF treatment for psoriasis is limited, and no published reports on this use exist. We describe a patient with metastatic colon cancer and psoriasis who experienced complete remission of psoriasis during treatment with bevacizumab and combination chemotherapy without any other treatment for psoriasis. These data suggest that bevacizumab may be a promising therapeutic agent for the treatment of psoriasis.
Oxford University Press